An investigation of the securities fraud was

New York, February 28, 2025 (Globe Newswire) – leading securities law firm Bleichmar Fonti & Auld LLP If an investigation by Teleflex Incorporated (NYSE: TFX), announces in order to obtain potential violations of the federal investment laws.

If you have invested in Teleflex, you will be asked to receive additional information by visiting .

Why is teleflex examined?

Teleflex is a global provider of medical technology products used by hospitals and health service providers for intensive care and surgical applications. On February 27, 2025, the company announced that its urology, Akum- and OEM companies in a new listed company, the resignation of its CFO, announced, and that for an estimated cash payment of around € 760 million after completing the entire vascular intervention business SE for an estimated cash payment of around EUR 760 million.

In view of these announcements, BFA examines whether teleflex and determined the high -ranking civil servants have made essential and misleading statements given the earlier positive representations of the company.

The share decreases when the truth is revealed

Due to the announcement of Teleflex on February 27, 2025, the company's share price decreased by about 20% during trade.

Click here to obtain more information: .

What can you do

If you have invested in Teleflex, you may have legal options and will be asked to send your information to the company.

All representation takes place on a eventual fee. There are no costs for you. The shareholders are not responsible for court costs or costs for legal disputes. The company will obtain approval for potential fees and expenses.

Send your information by visiting:

Or contact:
Ross Shikowitz
ross@bfalaw.com
212-789-3619

Why Bleichmar Fonti & Auld LLP?

Bleichmar Fonti & Auld LLP is a leading international law firm that represents the plaintiffs in securities and shareholder disputes. It was appointed the plaintiff's top 5 law firms in 2023, and his lawyers were appointed the plaintiffs and Superlawyers by Thompson Reuters by Thompson Reuters by Thompson Reuters. Among the recent remarkable successes, BFA achieved a value of over 900 million US dollars from the Tesla board of directors, Inc. and 420 million US dollars by Teva Pharmaceutical Ind. Ltd.

More information about BFA and his lawyers can be found under Viewing

Lawyer advertising. Past results do not guarantee future results.